---
title: "Alexion Pharmaceuticals, Inc. v Amgen Technology (Ireland) Unlimited Company and others (UPC CoA 405/2024, 08-08-2024)"
description: "A written pleading in UPC proceedings is served by the Registry through the Court's Case Management System (CMS), not by one party's lawyer sending it to the…"
url: https://pitch.law/academy/upc-court-of-appeal/upc-coa-405-2024-2024-08-08
lang: en
author: "UPC Case Law by Pitch"
editor: "Bart Lieben"
datePublished: 2026-11-18T10:07:14.177Z
dateModified: 2026-11-18T10:07:14.177Z
---

# Alexion Pharmaceuticals, Inc. v Amgen Technology (Ireland) Unlimited Company and others

Order of the UPC Court of Appeal of 8 August 2024, UPC CoA 405/2024.

UPC Case Law by Pitch, edited by [Bart Lieben](https://pitch.law/team/bart-lieben) · Published 18-11-2026

## TL;DR

A written pleading in UPC proceedings is served by the Registry through the Court's Case Management System (CMS), not by one party's lawyer sending it to the other side's lawyer through another electronic channel. The Court of Appeal fixed the service date of a statement of grounds of appeal as the day the CMS notified the respondents. An upload two days earlier to the respondents' representative's German beA mailbox did not count as service.

## Key holding

Under R 278.1 and 278.2 RoP, written pleadings, such as a statement of grounds of appeal, are served by the Registry in the Court's electronic Case Management System, unless service cannot be effected by electronic communication. Prior communication of the pleading between the parties themselves through another electronic system, such as the German special electronic lawyer's mailbox (besonderes elektronisches Anwaltspostfach, beA), cannot be considered effective service under R 278.1 RoP.

## Questions decided

1. Who serves written pleadings such as a statement of grounds of appeal under R 278 RoP?
2. Is sending a pleading directly to opposing counsel's beA mailbox effective service under R 278.1 RoP?
3. On what date was the statement of grounds of appeal served in this case?

## Case details

- Court: Court of Appeal of the Unified Patent Court
- Panel: Klaus Grabinski, President of the Court of Appeal, filling in as Judge-rapporteur (deciding judge)
- Date: 08-08-2024
- Case number(s): UPC CoA 405/2024, UPC CFI 124/2024
- Parties: Appellant: Alexion Pharmaceuticals, Inc. (applicant at first instance). Respondents: Amgen Technology (Ireland) Unlimited Company; Amgen N.V.; Amgen GmbH (Munich); Amgen GmbH (Vienna); Amgen AB; Amgen S.A.S.; Amgen s.r.l.; Amgen Biofarmacêutica Lda.; Amgen Zdravila D.O.O. (defendants at first instance).
- Language of the proceedings: English
- Outcome: The Court of Appeal ordered that, in this case, service of the statement of grounds of appeal was effected on 29 July 2024.
- Official text on the court’s website (PDF): https://www.unified-patent-court.org/sites/default/files/files/api_order/1866B3ED297FAF985BD82B5945677424_en.pdf

## How to cite

Court of Appeal, Alexion Pharmaceuticals, Inc. v Amgen Technology (Ireland) Unlimited Company and others, UPC CoA 405/2024, Order of 8 August 2024 (OSCOLA)

## Full summary

Read the full analyses for free — create a free account: https://pitch.law/academy/upc-court-of-appeal/upc-coa-405-2024-2024-08-08

Topics: [Procedure](https://pitch.law/academy/upc-court-of-appeal/topics/procedure)

## In the same case

- [Alexion Pharmaceuticals, Inc. v Amgen Technology (Ireland) Unlimited Company and others, UPC CoA 405/2024, 20-12-2024](https://pitch.law/academy/upc-court-of-appeal/upc-coa-405-2024-2024-12-20): The Court of Appeal rejected Alexion's appeal, so no provisional measures will be ordered against Amgen's eculizumab biosimilar BEKEMV®.

## More on procedure

- [PAUSTIAN & PARTNER Patentanwälte mbB v NUC Electronics Europe GmbH and others, UPC CoA 163/2026, 11-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-163-2026-2026-11-11): The Court of Appeal granted a patent law firm access to the statements of appeal and statements of grounds of appeal in three closed appeals concerning EP 2 028 981.
- [The Walt Disney Company and others v InterDigital VC Holdings, Inc., UPC CoA 133/2026, 05-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-133-2026-2026-11-05): A request under R 262A RoP to stop the other party from accessing or using confidential information cannot be made for the first time on appeal for material already filed at first instance.
- [Guardant Health, Inc. v Sophia Genetics SA and others, UPC CoA 49/2026, 05-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-49-2026-2026-11-05): The Court of Appeal set aside a EUR 600,000 award of representation costs because the successful party had backed it only with invoices reading "supply of legal services" and general assertions about complexity and urgency.
- [Netflix Services Germany GmbH and others v DivX, LLC, UPC CoA 176/2026, 02-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-176-2026-2026-11-02): The Court of Appeal refused Netflix's request for suspensive effect against the Munich Local Division's infringement decision in favour of DivX, even though the EPO Opposition Division revoked the patent after that decision.
- [Appellant (name not stated) v Amycel, LLC, UPC CoA 935/2025, 02-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-935-2025-2026-11-02): The Court of Appeal set aside a decision by default of The Hague Local Division and allowed the defendant's application to have it set aside under R 356 RoP.
